Movicol Chocolate

Macrogol 3350 with electrolytes, the active ingredient in Movicol Chocolate, is an osmotic laxative presented as a powder for oral solution for oral use. It is indicated for the treatment of constipation, including chronic constipation, in adults and children when prescribed by a healthcare professional.

GNH USA supplies Movicol Chocolate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required.

Movicol Chocolate, an osmotic laxative, is used to manage conditions affecting bowel regularity. - Constipation: provides relief by softening stool and promoting regular bowel movements. - Chronic constipation: helps maintain bowel regularity over long‑term use under medical supervision. - Opioid‑induced constipation: restores bowel function by counteracting opioid‑related reduction in intestinal water content. - Bowel preparation for diagnostic procedures: can be used under physician guidance to clear the colon before endoscopy.

The most frequently reported reactions to Movicol Chocolate are related to its osmotic activity and electrolyte content.

Common Side Effects: - Abdominal bloating: sensation of fullness or swelling in the abdomen. - Flatulence: increased intestinal gas leading to discomfort. - Nausea: feeling of sickness or urge to vomit. - Diarrhoea: loose, watery stools occurring after use. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Severe dehydration: marked loss of body fluids requiring medical attention. - Electrolyte imbalance: abnormal levels of sodium, potassium or chloride that may cause cardiac or neuromuscular issues. - Allergic reaction: rash, itching, swelling or difficulty breathing. - Persistent abdominal pain: intense pain that does not resolve. - Blood in stool: presence of visible blood indicating possible gastrointestinal injury.

Before prescribing Movicol Chocolate, healthcare professionals should consider several safety aspects to minimise risks. - Renal function assessment: evaluate kidney performance, especially in patients with existing renal impairment. - Electrolyte monitoring: check serum sodium, potassium and chloride levels during prolonged therapy. - Dehydration risk: avoid use in individuals who are already dehydrated or have fluid loss. - Intestinal obstruction: contraindicated in patients with known bowel blockage or perforation. - Elderly dosing: start with the lowest effective dose and monitor tolerance in older adults. - Store at ambient temperature: keep in the original packaging, protect from moisture and excessive heat.

Movicol Chocolate may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with other osmotic laxatives: may cause severe electrolyte disturbances and dehydration. - High‑dose potassium supplements: risk of hyperkalaemia due to added potassium chloride. - Loop diuretics: combined effect can lead to significant electrolyte loss.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal function, increasing risk of fluid imbalance. - ACE inhibitors or ARBs: monitor blood pressure and electrolytes as the laxative can modify sodium levels. - Antacids containing sodium: may increase sodium load, requiring electrolyte monitoring.